Algert Global’s Acrivon Therapeutics ACRV Stock Holding History

Algert Global’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-44,648	Closed	-$81K	–	1123
2025 Q3	$81K	Buy	+44,648	New	+$62.8K	﹤0.01%	1096

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Algert Global's ACRV Position: Q4 2025 in Review

Algert Global sold out of Acrivon Therapeutics (ACRV) in Q4 2025, closing a stake of 44,648 shares — an estimated $81K sold.

Algert Global first reported a position in ACRV in Q3 2025 and held it in 1 quarter. The position peaked at $81K in Q3 2025. 48 funds tracked by Wall St. Rank hold ACRV as of Q4 2025.

Algert Global reported no remaining Acrivon Therapeutics position as of Q4 2025 after selling out during the quarter.
Algert Global sold 44,648 Acrivon Therapeutics shares in Q4 2025, an estimated $81K.
Algert Global first reported a position in Acrivon Therapeutics in Q3 2025 and held it in 1 quarter.
Algert Global's Acrivon Therapeutics position peaked at $81K in Q3 2025.
48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q4 2025.

Based on Algert Global's 13F filing for Q4 2025, filed 17 Feb 2026.